Ten months after a quick FDA nod, Novartis' next-generation leukemia drug Scemblix has won a European Commission approval for Philadelphia chromosome-positive chronic myeloid leukemia (CML) after two or more prior tyrosine kinase inhibitors.
Novartis (NOVN.S) said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting savings of at least $1 billion by 2024.
